Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

NCT07728396

Active Not RecruitingPhase 1

Sponsor: GC Biopharma Corp

Conditions: COVID - 19

Interventions: GC4006A, Normal Saline

Countries: South Korea

A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years

Eligibility overview

Sex: ALL

Age: 19 Years to 64 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Age 19-64 with written informed consent
* ≥16 weeks since last COVID-19 vaccination

Exclusion Criteria:

* Positive SARS-CoV-2 test (RT-PCR/Rapid Antigen) at screening or randomization
* \<16 weeks since COVID-19 diagnosis
* History of serious adverse event, allergy, or hypersensitivity to the vaccines
* Pregnant or lactating women
Locations (1)
  • Seoul, South Korea